Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma

Glioblastoma (GBM) is an aggressive primary brain tumor that is associated with a poor prognosis and quality of life. The standard of care has changed minimally over the past two decades and currently consists of surgery followed by radiotherapy (RT), concomitant and adjuvant temozolomide, and tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsui, Jennifer K., Perlow, Haley K., Ritter, Alex R., Upadhyay, Rituraj, Raval, Raju R., Thomas, Evan M., Beyer, Sasha J., Pillainayagam, Clement, Goranovich, Justin, Ong, Shirley, Giglio, Pierre, Palmer, Joshua D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313399/
https://www.ncbi.nlm.nih.gov/pubmed/35885067
http://dx.doi.org/10.3390/biomedicines10071763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313399/
https://www.ncbi.nlm.nih.gov/pubmed/35885067
http://dx.doi.org/10.3390/biomedicines10071763

Ejemplares similares